Crescent Biopharma Raises $125M in Public Offering of Shares and Warrants — Crescent Biopharma, Inc.

Event summary

Crescent Biopharma priced a public offering of 8,094,793 ordinary shares and pre-funded warrants to purchase up to 525,897 additional shares.
The offering is expected to raise approximately $125 million in gross proceeds before expenses.
Shares were sold at $14.50 per share, with pre-funded warrants priced at $14.499 each.
Underwriters have a 30-day option to purchase up to an additional 1,293,103 ordinary shares.
The offering is expected to close on July 16, 2026.

The big picture

Crescent Biopharma's $125 million public offering reflects the ongoing need for biotech companies to secure substantial capital to fund late-stage clinical trials and potential commercialization. The deal underscores investor appetite for oncology-focused assets, particularly those targeting solid tumors with innovative modalities like bispecific antibodies and ADCs.

What we're watching

Capital Deployment: How Crescent Biopharma will allocate the $125 million in proceeds to advance its clinical-stage oncology pipeline, particularly its lead PD-1 x VEGF bispecific antibody and novel ADCs.
Market Performance: Whether the additional 30-day option for underwriters to purchase more shares will be exercised, indicating continued investor interest.
Pipeline Progress: The pace at which Crescent Biopharma can translate this funding into clinical milestones and regulatory approvals for its cancer therapies.